Company intelligence / Profile preview
Harbour BioMed
Cambridge, Massachusetts, United Statesharbourbiomed.com ↗
- Ownership
- Private
- Development stage
- Phase 3
01
Overview
The company has multiple programs in clinical development, including Batoclimab (HBM9161), porustobart (HBM4003), HBM7008, and HBM1020. They reported profitability in 2024 with total profit expected between RMB7.3-22 million and a record-high cash profit of RMB220 million.
- Therapeutic areas
- OncologyImmunology
- Modalities
- Antibody therapeuticsmonoclonal antibodiesbispecific antibodiesADC (Antibody-Drug Conjugates)RDC
- Industry
- Biotech
02
Drug pipeline
21 assets20 more assets in the full pipeline.
03
Partnerships
Beyond the preview
Go deeper on Harbour BioMed.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Harbour BioMed.